NCT01428440终止2 期
A Positron Emission Tomography (PET) Study to Evaluate 18FML10 as an Imaging Agent for Tumour Apoptosis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 7
- 试验地点
- 3
- 主要终点
- Apoptosis imaging
研究概览
简要总结
Apoptosis or programmed cell death is disrupted in cancer cells allowing them to live longer. A number of anti-cancer agents induce apoptosis as a mechanism of drug action to get rid of cancers. A biomarker that would allow apoptosis in tumours to be imaged directly would provide a powerful new tool for oncology drug development and potentially contribute to improved patient care. In this study, we propose to evaluate [18F]ML10-PET for imaging tumour apoptosis in patients receiving standard chemotherapy treatment for their cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients >18 years of age at screening with histological or cytological diagnosis of non-Hodgkin's lymphoma, small cell lung cancer, breast or ovarian cancer who have been worked up clinically (see below) and due to receive standard chemotherapy treatment, but enrolled prior to the initiation of chemotherapy.
- •A female subject is eligible to participate if she is of non-childbearing potential or if she is of childbearing potential and agrees to use one of the contraception methods listed. Male subjects are eligible to participate if he also agrees to use one of the contraception methods listed.
- •Tumour that is considered by the investigator to be able to be imaged using PET (about 2cm in size or more)
- •Able to lie comfortably on back for up to 65 minutes at a time.
- •Capable of giving written informed consent, and willing and able to comply with the requirements and restrictions listed in the consent form.
- •Patients deemed to be fit to receive chemotherapy treatment by their oncologist.
- •WHO performance status 0, 1 or 2.
排除标准
- •Any medical or psychiatric diagnoses or symptoms or social situations that in the view of the investigator would limit compliance with study requirements.
- •Pregnant or breast feeding females.
- •Received any other anticancer therapy (radiotherapy, chemotherapy, or immunotherapy) or any other investigational agent, including an investigational anti-cancer agent within 28 days prior to the first [18F]ML10-PET scan.
- •History of sensitivity to heparin or heparin-induced thrombocytopenia.
- •Inability to comply with contraceptive guidelines during the study.
结局指标
主要结局
Apoptosis imaging
时间窗: 2.5 years
Evaluate feasibility of apoptosis imaging with \[18F\]ML10 PET/CT in
次要结局
- Image optimisation time(2.5 years)
- [18F]ML10 tumour uptake(2.5 years)
- serum markers(2.5 years)
- Oncology patients(2.5 years)
- Develop Imaging protocols(2.5 years)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1Head and Neck CancerDiffuse Large B-cell LymphomaBreast CancerNCT00968656Washington University School of Medicine31
已完成
不适用
Role of Positron Emission Tomography in the Evaluation of Response to Sorafenib in Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT01157013Hospital Miguel Servet40
终止
不适用
Pilot Study of (61)CuATSM-PET Imaging in Cancer PatientsCNS Brain MetastasesHead and Neck CancerProstate CancerLung CancerEsophageal CancerNCT00585117University of Wisconsin, Madison9
已完成
3 期
PET Imaging in Potentially Surgically Resectable Non-small Cell Lung CancersNon-small-cell Lung CarcinomaNCT00136890Ontario Clinical Oncology Group (OCOG)337
招募中
不适用
Circulating tumor cells to predict survival and monitor treatment response in patients with advanced HCCDRKS00029565Klinikum der Universität München, Campus Großhadern70